![Sample our Behavioral Sciences journals, sign in here to start your access, latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/110801/TOC-Subject-Sample-2021-Behavioral-Sciences.jpg"})
Abstract
Objectives: It is now widely accepted that ADHD is a frequent chronic condition with a lifelong perspective. Adult ADHD is a reliable and valid diagnosis. The disorder and the co-morbid conditions can place a severe burden on the patients, their families and their partners, requiring adequate treatment. Methods: A systematic literature search was conducted to review the available pharmacological treatment options for adults with ADHD in European countries. Results: Supported by meta-analyses, stimulant medication is the first-line pharmacological therapy for adult ADHD. However, from a European perspective the pharmacological treatment options are very limited and only a minority of adults with ADHD in European countries receives adequate treatment. Conclusions: With reference to the epidemiological data, it seems very likely that the number of people with ADHD in Europe seeking multimodal treatment including pharmacotherapy, psychotherapy, coaching or other therapeutic services will increase profoundly during the coming years.
Key words::
Acknowledgements
None
Declaration of interest: WR has received lecture and consulting fees from Medice and Lilly and funding from Novartis. PRJ has received honoraria from Lilly. JT is expert adviser for Shire and has received funding from AstraZeneca, Bristol-Myers Squibb, Janssen-Cilag, Lilly, Lundbeck, Medice, Merz, Novartis, Pfizer and Servier. MR is a member of the advisory boards and of the speakers bureau of Medice, Janssen-Cilag, Shire and Lilly and has received funding from Medice.